Financing ·
Cogent Biosciences filed a prospectus supplement to register the offer and sale of up to $400 million in shares of…
COGTCogent Biosciences, Inc.
Cogent Biosciences filed a prospectus supplement to register the offer and sale of up to $400 million in shares of common stock under an existing at-the-market offering agreement with Guggenheim Securities. This filing supplements the company's automatic shelf registration statement on Form S-3ASR, which became effective upon filing on November 7, 2025. The company has obtained a legal opinion from Gibson, Dunn & Crutcher LLP regarding the shares. Cogent Biosciences operates in the biotechnology industry, focusing on developing therapies for rare genetic diseases.